Investigational Drug Information for Triapine
What is the development status for investigational drug Triapine?
Triapine is an investigational drug.
There have been 35 clinical trials for Triapine.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2026.
The most common disease conditions in clinical trials are Adenocarcinoma, Vaginal Neoplasms, and Uterine Cervical Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Vion Pharmaceuticals, and NRG Oncology.
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Triapine
| US Patents | 1,200 |
| International Patents | 8,883 |
| US Patent Applications | 2,835 |
| WIPO Patent Applications | 1,166 |
| Japanese Patent Applications | 436 |
| Clinical Trial Progress | Phase 2 (2026-03-01) |
| Vendors | 53 |
Recent Clinical Trials for Triapine
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | National Cancer Institute (NCI) | PHASE1 |
| Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | BrainUp Inc | PHASE1 |
| Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | National Cancer Institute (NCI) | PHASE1 |
Clinical Trial Summary for Triapine
Top disease conditions for Triapine
Top clinical trial sponsors for Triapine
US Patents for Triapine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Triapine | ⤷ Start Trial | Formulations for tailored drug release | South Dakota Board of Regents (Pierre, SD) Sanford Health (Sioux Falls, SD) | ⤷ Start Trial |
| Triapine | ⤷ Start Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Start Trial |
| Triapine | ⤷ Start Trial | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (San Diego, CA) | ⤷ Start Trial |
| Triapine | ⤷ Start Trial | Treatment of solid tumours | VIVOLUX AB (Uppsala, SE) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Triapine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Triapine | World Intellectual Property Organization (WIPO) | WO2016065255 | 2034-10-23 | ⤷ Start Trial |
| Triapine | Canada | CA2922341 | 2033-08-28 | ⤷ Start Trial |
| Triapine | European Patent Office | EP3038618 | 2033-08-28 | ⤷ Start Trial |
| Triapine | World Intellectual Property Organization (WIPO) | WO2015031608 | 2033-08-28 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
Triapine Development Update and Market Projection
Triapine is an investigational ribonucleotide reductase inhibitor with no FDA approval, no commercial product revenue, and no established generic or biosimilar market. Its leading development program in locally advanced cervical cancer failed to demonstrate a clinically meaningful benefit in the randomized NRG-GY006 study. The result materially reduces the probability of approval and limits the near-term commercial opportunity to small, sponsor-led salvage or biomarker-defined studies.
What is the current development status of Triapine?
Triapine, also known as 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, is an iron-chelating inhibitor of ribonucleotide reductase. The mechanism reduces deoxyribonucleotide availability, impairs DNA synthesis, and can increase tumor sensitivity to radiation and DNA-damaging chemotherapy.
The clinical development record spans hematologic malignancies and solid tumors, including:
- Acute myeloid leukemia and myelodysplastic syndromes
- Pancreatic cancer
- Non-small-cell lung cancer
- Ovarian cancer
- Glioblastoma
- Locally advanced cervical cancer
- Other radiation-sensitive solid tumors
Triapine has been studied as an intravenous agent, usually in combination with chemotherapy or radiation. It has not reached an FDA-approved indication.
The most advanced program was NRG-GY006, a randomized phase III study evaluating triapine with cisplatin and radiation therapy in locally advanced cervical cancer. The trial tested whether adding triapine to standard chemoradiation could improve overall survival and progression-free survival. Publicly reported results indicated that the study did not meet its primary efficacy objective. NRG Oncology and the National Cancer Institute identified no basis for regulatory advancement of triapine in this setting based on the phase III result (ClinicalTrials.gov, 2024; NRG Oncology, 2023).
Triapine development timeline
| Period | Development event | Commercial relevance |
|---|---|---|
| 1990s | Preclinical and early clinical development of 3-AP begins | Composition-of-matter patent life largely predates current development |
| 2000s | Phase I and phase II studies in leukemia and solid tumors | Established a broad but fragmented clinical profile |
| 2010s | Radiation-sensitization studies expand, particularly in cervical cancer | Shifted focus toward combination therapy |
| 2016 | NRG-GY006 phase III cervical-cancer study initiated | First major registration-oriented test |
| 2020s | Phase III results fail to show a meaningful benefit | Substantially reduces approval probability |
| Current status | No FDA-approved indication and no marketed product | Commercial value depends on a new development strategy |
Did Triapine succeed in the phase III cervical cancer trial?
No. Triapine did not establish a positive phase III efficacy profile in locally advanced cervical cancer.
The rationale for NRG-GY006 was strong from a mechanistic standpoint. Ribonucleotide reductase supports DNA repair and replication, while radiotherapy creates DNA damage. Triapine was intended to inhibit DNA repair capacity and improve tumor response to cisplatin-based chemoradiation.
The trial outcome did not support that strategy as a broad treatment approach. The failure has several implications:
- A cervical-cancer approval pathway is unlikely without a new confirmatory study.
- The standard-of-care regimen remains external-beam radiation, brachytherapy, and concurrent cisplatin or an alternative platinum regimen.
- Further investment would require a biomarker strategy, a revised dosing schedule, or a different therapeutic combination.
- The phase III failure weakens the value of prior phase II response and survival signals.
The result does not prove that triapine has no activity in every disease. It does show that broad development in cervical cancer is not commercially supportable without new clinical evidence.
What patents protect Triapine?
Triapine is an old small molecule, and its principal composition-of-matter patent protection is expected to have expired or to be close to expiration in major markets.
The historical patent position is different from that of a recently discovered oncology drug:
| Protection category | Likely position for Triapine | Commercial impact |
|---|---|---|
| Composition of matter | Early patents associated with 3-AP and related thiosemicarbazones are old | Little or no remaining basic molecule exclusivity |
| Manufacturing process | Possible process claims may exist | Usually insufficient to block independent synthesis |
| Formulation | Potential opportunity for injectable stability, infusion, or delivery claims | Could provide limited, product-specific protection |
| Method of use | Potential claims covering radiation combinations or selected cancers | Dependent on patent validity and clinical differentiation |
| Biomarker selection | Possible future claims for genetically or metabolically defined tumors | Main route to new proprietary protection |
| Regulatory exclusivity | None publicly established | No current FDA market protection |
The public development record does not establish a current, broad U.S. composition patent that would block a third party from making triapine. Any remaining patent value is more likely to reside in new formulations, dosing regimens, combinations, or patient-selection methods than in the active pharmaceutical ingredient itself.
A company seeking to restart development would need to build a secondary patent estate. Potential claim areas include:
- Triapine with radiotherapy and immune checkpoint blockade
- Triapine with cisplatin or carboplatin under a defined schedule
- Use in tumors with high replication stress
- Use in tumors with elevated ribonucleotide reductase activity
- Nanoparticle or liposomal delivery
- Reduced-toxicity infusion formulations
- Combination treatment in tumors with defective DNA damage response pathways
Those patents would face written-description, enablement, obviousness, and clinical-predictability challenges. The NRG-GY006 failure would also complicate broad method-of-use claims in cervical cancer.
What is the Orange Book status of Triapine?
Triapine is not listed as an FDA-approved drug in the Orange Book. It has no approved reference listed drug, no approved abbreviated new drug application, and no Orange Book patent listing associated with an FDA-approved product (U.S. Food and Drug Administration, 2024a).
The practical consequences are significant:
- There is no current Orange Book patent-certification framework for triapine.
- No Paragraph IV challenge is publicly relevant to an approved triapine product.
- No 30-month stay is available because no approved reference product exists.
- Any future generic application would first require an approved reference product or a different regulatory pathway.
- A future sponsor would need to establish safety and efficacy through a new drug application or another applicable pathway.
Triapine is a small molecule, so biosimilar regulation does not apply. A follow-on product would be a generic or hybrid small-molecule product, not a biosimilar.
When does Triapine lose exclusivity?
Triapine has already lost practical composition-of-matter exclusivity in the United States and other major markets, based on the age of the molecule and its early patent history. No current commercial exclusivity clock is running because the drug has not received FDA approval.
If a sponsor obtained a new approval, possible exclusivity would depend on the approval basis:
| Potential FDA protection | Typical duration | Applicability |
|---|---|---|
| New chemical entity exclusivity | 5 years | Unlikely for an old, previously studied molecule |
| Orphan-drug exclusivity | 7 years | Possible only with a qualifying orphan indication |
| New clinical investigation exclusivity | 3 years | Potentially relevant for a new formulation or indication |
| Pediatric exclusivity | 6 additional months | Requires an FDA pediatric-study request |
| Patent protection | Up to 20 years from relevant filing date | Available only for new, valid inventions |
An orphan designation would not restore broad molecule protection. It could provide seven years of indication-specific exclusivity after approval, but only for the approved orphan indication and only against the same drug for the same use.
Which companies are developing or challenging Triapine?
Triapine has not developed into a competitive commercial market with multiple active sponsors. Its historical clinical development was associated with Vion Pharmaceuticals and cooperative-group or government-supported oncology research. Later work has largely involved academic institutions, the National Cancer Institute, and cooperative oncology networks rather than large pharmaceutical companies with marketed oncology portfolios.
There is no established public record of:
- A currently marketed Triapine product
- A major pharmaceutical licensing transaction tied to a commercial launch
- A competing approved Triapine formulation
- A Paragraph IV generic challenge
- A biosimilar development program
- Active commercial litigation over a Triapine product
The absence of commercial challengers reflects the drug's status. A generic company has little incentive to challenge patents for a product that lacks FDA approval, market exclusivity, and a demonstrated registration path.
What formulation patents could protect Triapine?
Formulation protection is the clearest potential route to new intellectual property, but the commercial value would depend on clinical differentiation.
Triapine has historically been administered intravenously. A new sponsor could pursue:
Injectable formulation protection
Claims could cover concentration, pH, solvent composition, excipient selection, storage stability, or infusion compatibility. These claims may be useful if the existing formulation has precipitation, stability, infusion-time, or handling limitations.
Oral delivery
An oral formulation could expand outpatient use and simplify combination treatment. Oral development would require proof of adequate bioavailability, exposure control, and tolerability. It could support a three-year period of clinical investigation exclusivity after approval if the FDA requirements were satisfied, but the underlying active ingredient would remain unprotected.
Targeted delivery
Liposomes, polymeric nanoparticles, antibody-drug conjugate-like systems, or tumor-targeted carriers could produce new patentable subject matter. The clinical and manufacturing burden would be high, and the delivery system could alter the pharmacology that supported prior radiation studies.
Combination products
A fixed-dose or co-packaged product with cisplatin would be commercially difficult because of differing administration requirements and toxicity profiles. Separate-drug combination claims are more realistic than a fixed-dose product.
What regulatory risks affect Triapine?
The main regulatory risk is efficacy, not basic feasibility. Triapine has a substantial clinical history, but historical studies were heterogeneous in dose, disease, combination partner, and endpoint selection.
Key risks include:
- Failure to reproduce early response signals
- Lack of a validated predictive biomarker
- Overlapping hematologic and systemic toxicities with chemotherapy
- Difficulty separating triapine activity from radiation or platinum activity
- Limited commercial rationale for a broad, unselected population
- Need for a new pivotal study after the phase III result
- Potentially narrow therapeutic index in combination treatment
FDA approval would likely require a clearly defined disease setting, clinically meaningful endpoints, and a reproducible dosing regimen. A single-arm accelerated-approval strategy could be considered only if the sponsor identified a highly responsive population and a suitable surrogate endpoint. The phase III failure makes that path less credible in unselected cervical cancer.
What market could Triapine reach?
Triapine's addressable market is currently theoretical because it has no approval or sales. The most credible opportunity would be a niche oncology indication rather than a broad commercial launch.
Cervical cancer opportunity
The United States records roughly 13,000 to 14,000 new cervical cancer cases annually. Only a subset has locally advanced disease treated with definitive chemoradiation. The global population is much larger, but access to radiation, brachytherapy, and combination treatment varies widely (American Cancer Society, 2024).
A successful product in this setting might treat several thousand U.S. patients annually. At a hypothetical net treatment price of $10,000 to $25,000, the U.S. opportunity would be approximately:
| Scenario | Treated U.S. patients | Net price per course | Annual U.S. revenue |
|---|---|---|---|
| Low | 2,000 | $10,000 | $20 million |
| Base | 4,000 | $15,000 | $60 million |
| High | 6,000 | $25,000 | $150 million |
These figures represent scenario analysis, not reported market revenue. The phase III failure makes the high case commercially remote without a new efficacy signal.
Biomarker-selected opportunity
A biomarker-defined indication could produce a smaller but more defensible market. If triapine activity were confirmed in a subset representing 5% to 15% of patients with a selected solid tumor, annual U.S. sales could fall in the $25 million to $100 million range depending on pricing and treatment duration.
Global opportunity
A global launch could expand patient volume, particularly in cervical cancer, but lower pricing and infrastructure constraints would reduce revenue per patient. A plausible commercial range for a successfully approved, niche indication would be approximately $75 million to $250 million in peak worldwide sales. The probability-adjusted value is far lower because the drug still requires a viable development program after a negative phase III result.
How strong is the Triapine patent estate?
The patent estate is weak for broad product exclusivity and potentially moderate for newly created use or formulation claims.
| Factor | Assessment |
|---|---|
| Active ingredient protection | Weak |
| Patent life | Limited for historical molecule claims |
| Orange Book leverage | None |
| Formulation opportunity | Moderate |
| Method-of-use opportunity | Moderate but dependent on data |
| Biomarker opportunity | Potentially meaningful |
| Manufacturing barriers | Low to moderate |
| Regulatory exclusivity | Not currently available |
| Litigation leverage | Low |
| Commercial defensibility | Low without new proprietary formulation or biomarker |
Manufacturing is unlikely to be a durable barrier. Triapine is a relatively small, chemically defined molecule, and independent synthesis is likely feasible for qualified manufacturers. A sponsor would need to rely on quality systems, clinical data, regulatory execution, and secondary patents rather than manufacturing complexity.
What generic entry risks exist for Triapine?
Generic entry risk is structurally high after approval because the active molecule is old and no broad composition patent appears to provide a long runway.
The key distinction is timing:
- Before approval, generic entry is not the primary risk because there is no established reference product.
- After approval, a generic could seek approval once applicable patents and exclusivities expire.
- A strong formulation patent could delay substitution if the approved product depends on that formulation.
- A method-of-use patent may not block all generic use if the label can be carved out.
- An orphan exclusivity period could protect a defined indication even without broad composition protection.
A future sponsor would therefore need to design the label and clinical program around claims that are difficult to carve out and difficult to design around.
What patent litigation and settlement agreements affect Triapine?
No material public patent litigation or Paragraph IV settlement is associated with a marketed Triapine product. The lack of litigation is consistent with the absence of FDA approval and Orange Book listings.
There is also no established public settlement framework between an originator and generic applicant. Any future dispute would more likely involve:
- Validity of a new formulation patent
- Obviousness of a triapine-radiation combination
- Written description for biomarker-selected treatment
- Enablement across multiple tumor types
- Label-skinnying and induced infringement
- Ownership of clinical data or cooperative-group inventions
How does Triapine compare with competing oncology strategies?
Triapine competes with established approaches rather than with another approved ribonucleotide reductase inhibitor.
| Strategy | Development position | Competitive implication |
|---|---|---|
| Cisplatin-based chemoradiation | Standard backbone in locally advanced cervical cancer | Triapine must add survival or durable disease control |
| Carboplatin-based chemoradiation | Alternative for selected patients | Limits differentiation based only on platinum compatibility |
| Pembrolizumab-containing regimens | Established immuno-oncology competition in cervical cancer | Raises the efficacy threshold for new combinations |
| Topotecan or gemcitabine combinations | Used in selected recurrent settings | Greater need for biomarker selection |
| Hydroxyurea and other ribonucleotide-reductase approaches | Mechanistically related but clinically distinct | Triapine requires better therapeutic index or radiosensitization |
| PARP, ATR, WEE1, and DNA-damage-response inhibitors | Active development classes | Compete for the same precision-oncology positioning |
Triapine's strongest differentiator is its potential role as a radiosensitizer. Its weakness is the absence of validated patient selection and the failure of the largest registration-directed study.
Key Takeaways
- Triapine is an investigational small-molecule ribonucleotide reductase inhibitor with no FDA approval.
- The phase III NRG-GY006 cervical-cancer study did not establish a meaningful clinical benefit.
- No Orange Book listing, Paragraph IV challenge, biosimilar program, or commercial product litigation is publicly established.
- Broad composition-of-matter protection is not expected to provide meaningful current exclusivity.
- New formulation, biomarker, and combination patents are the main potential sources of future protection.
- A successful commercial indication would likely be niche, with an estimated peak worldwide opportunity of roughly $75 million to $250 million under favorable clinical and regulatory assumptions.
- The probability-adjusted value remains low without a new development program showing reproducible benefit in a defined patient population.
- Generic entry risk would be high after any future approval unless the sponsor secures strong formulation, method-of-use, or orphan exclusivity protection.
FAQs
Is Triapine approved for cervical cancer?
No. Triapine is not FDA-approved for cervical cancer or any other indication.
Is Triapine a chemotherapy drug or a targeted therapy?
Triapine is a targeted small-molecule inhibitor of ribonucleotide reductase, but it has been developed primarily in combination with chemotherapy and radiation rather than as a standalone targeted therapy.
Can Triapine be prescribed commercially?
No approved commercial prescription product has been established in the United States. Its use has been limited to clinical research and investigational programs.
Does Triapine have orphan-drug exclusivity?
No active FDA orphan-drug exclusivity period is established for a marketed Triapine product. Orphan designation, if granted for a particular investigational use, would not itself create approval or commercial exclusivity.
What would be required to revive Triapine development?
A viable revival strategy would require a new sponsor, a defined clinical niche, a reproducible biomarker or combination rationale, a proprietary formulation or use patent position, and clinical data that address the negative phase III cervical-cancer result.
References
-
American Cancer Society. (2024). Cancer facts & figures 2024. American Cancer Society.
-
ClinicalTrials.gov. (2024). NCT02466971: Triapine in combination with cisplatin and radiation therapy in patients with locally advanced cervical cancer. U.S. National Library of Medicine.
-
National Cancer Institute. (2024). Triapine. Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute.
-
NRG Oncology. (2023). NRG-GY006: A randomized phase III study of triapine with cisplatin and radiation therapy in locally advanced cervical cancer. NRG Oncology.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024b). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
More… ↓
